These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26163429)

  • 1. Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes.
    Espeland MA; Brinton RD; Manson JE; Yaffe K; Hugenschmidt C; Vaughan L; Craft S; Edwards BJ; Casanova R; Masaki K; Resnick SM;
    Neurology; 2015 Sep; 85(13):1131-8. PubMed ID: 26163429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women.
    Espeland MA; Brinton RD; Hugenschmidt C; Manson JE; Craft S; Yaffe K; Weitlauf J; Vaughan L; Johnson KC; Padula CB; Jackson RD; Resnick SM;
    Diabetes Care; 2015 Dec; 38(12):2316-24. PubMed ID: 26486190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study.
    Resnick SM; Espeland MA; Jaramillo SA; Hirsch C; Stefanick ML; Murray AM; Ockene J; Davatzikos C
    Neurology; 2009 Jan; 72(2):135-42. PubMed ID: 19139364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies.
    Coker LH; Espeland MA; Hogan PE; Resnick SM; Bryan RN; Robinson JG; Goveas JS; Davatzikos C; Kuller LH; Williamson JD; Bushnell CD; Shumaker SA;
    Neurology; 2014 Feb; 82(5):427-34. PubMed ID: 24384646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
    Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
    JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
    Rapp SR; Espeland MA; Shumaker SA; Henderson VW; Brunner RL; Manson JE; Gass ML; Stefanick ML; Lane DS; Hays J; Johnson KC; Coker LH; Dailey M; Bowen D;
    JAMA; 2003 May; 289(20):2663-72. PubMed ID: 12771113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
    Espeland MA; Rapp SR; Shumaker SA; Brunner R; Manson JE; Sherwin BB; Hsia J; Margolis KL; Hogan PE; Wallace R; Dailey M; Freeman R; Hays J;
    JAMA; 2004 Jun; 291(24):2959-68. PubMed ID: 15213207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
    J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain volumes, cognitive impairment, and conjugated equine estrogens.
    Espeland MA; Tindle HA; Bushnell CA; Jaramillo SA; Kuller LH; Margolis KL; Mysiw WJ; Maldjian JA; Melhem ER; Resnick SM;
    J Gerontol A Biol Sci Med Sci; 2009 Dec; 64(12):1243-50. PubMed ID: 19729392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study.
    Coker LH; Hogan PE; Bryan NR; Kuller LH; Margolis KL; Bettermann K; Wallace RB; Lao Z; Freeman R; Stefanick ML; Shumaker SA
    Neurology; 2009 Jan; 72(2):125-34. PubMed ID: 19139363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone Therapy Use and Risk of Chronic Disease in the Nurses' Health Study: A Comparative Analysis With the Women's Health Initiative.
    Bhupathiraju SN; Grodstein F; Rosner BA; Stampfer MJ; Hu FB; Willett WC; Manson JE
    Am J Epidemiol; 2017 Sep; 186(6):696-708. PubMed ID: 28938710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of stroke in healthy postmenopausal women during and after hormone therapy: a meta-analysis.
    Gu H; Zhao X; Zhao X; Yang Y; Lv X
    Menopause; 2014 Nov; 21(11):1204-10. PubMed ID: 24686450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
    Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen plus progestin and risk of venous thrombosis.
    Cushman M; Kuller LH; Prentice R; Rodabough RJ; Psaty BM; Stafford RS; Sidney S; Rosendaal FR;
    JAMA; 2004 Oct; 292(13):1573-80. PubMed ID: 15467059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
    Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
    Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM
    Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
    Cauley JA; Robbins J; Chen Z; Cummings SR; Jackson RD; LaCroix AZ; LeBoff M; Lewis CE; McGowan J; Neuner J; Pettinger M; Stefanick ML; Wactawski-Wende J; Watts NB;
    JAMA; 2003 Oct; 290(13):1729-38. PubMed ID: 14519707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.